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Abstract 
Brain tumors represent the most 
frequent solid malignancy in children and 
the first cause of cancer-related deaths in 
pediatric population. Supratentorial 
neuroectodermal tumor (PNET) represents 
one of the most aggressive brain tumors at 
this age. Incidence of S-PNET is 2-3% of 
all brain tumors in children, but reaches up 
to 20% of brain tumors in 0 - 3 years old 
children. Although in the last years the 
outcome has improved, the prognosis 
remains dismal. We choose to present the 
case of a 4 years old child who was at 
presentation in a comatose state (GCS 4 
points) with anisocoria (right pupil was 
mydriatic). The performed head CT-scan 
showed a right fronto-parietal tumor with 
intratumoral hemorrhage, maximal 
dimensions of 52/75/70 mm and a midline 
shift of 15 mm. The surgery was performed 
in emergency and we made a gross total 
resection. Immediate postoperative CT-
scan confirmed the total resection. The 
histopathological diagnosis was S-PNET, 
this result being confirmed by 
immunochemistry. After neuromotor 
rehabilitation, at the 4 month follow-up 
visit the GOS was MD. The patient was 
also referred to the oncologist and was 
made chemotherapy and radiotherapy of 
the entire craniospinal axis. The tumor 
showed no signs of recurrence during 12 
months of follow-up. 
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Introduction 
Supratentorial PNET is one of the most 
aggressive brain tumors in the pediatric 
population. It represents 2-3% of all brain 
tumors in children, this percent rising up to 
20% in the 0 - 3 years old population. Due 
to the small incidence, the relative recent 
description of this entity (S-PNET was 
firstly described in 1973, while the first 
description of medulloblastomas dates from 
1925) and the fact that in the WHO 
classification those tumors were discordant, 
there are few data in the literature 
concerning this subject when comparing 
with medulloblastomas. The highest 
incidence of S-PNET is at young age. Signs 
and symptoms at presentation are seizures, 
signs of intracranial hypertension, focal 
neurologic deficits. Although in the last 
years the management of these cases has 
improved, the outcome is very poor.  
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Case presentation 
History and presentation: A four years 
child was admitted in the clinic in coma, 
GCS 4 points, with anisocoria (right pupil 
was mydriatic). The patient had headaches, 
debuted 5 months before, and nausea 
vomiting for 3 days before admission in the 
hospital, those being diagnosed as 
gastrointestinal disorders. In the day of 
admission the child went to bed and did not 
wake up. Before these 5 months, she had no 
history of medical problems. 
Clinical and neurological examination: 
The patient was in coma, GCS 4 points, 
with anisocoria (right pupil was mydriatic), 
Babinsky positive on the right side, 
hemodynamically stable, intubated oro-
tracheal and mechanically ventilated 
(CPAP). 
Neuroimaging investigations: A brain 
CT-scan was performed, which revealed a 
fronto-parietal mass, heterogeneous, with 
areas of hemorrhage, without contrast 
enhancement and minimal surrounding 
edema, maximal dimensions of 52/75/70 
mm and a midline shift of 15 mm (Figure 
1, 2). Due to the neurological and clinical 
state we did not performed a preoperative 
brain MRI.  
 
Figure 1 Preoperative native CT-scan 
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Figure 2 Preoperative CT-scan with contrast enhancement 
 
Operation: We operated the child in 
emergency. A fronto-parietal bone flap was 
made, dura mater, in tension, was incised 
semicircular with medial pedicle. We found 
a fronto-parietal tumor heterogenous, 
friable, with intratumoral hemorrhage, with 
a diameter of approximately 7 cm. We made 
gross total excision. At the end of the 
operation the brain was collapsed, pulsatile. 
Dura mater was sutured in “water-tight” 
fashion, and the bone flap was fixated. The 
surgical intervention lasts 3 hours and 45 
minutes and the blood loss was 300 ml.  
Postoperative course: Postoperative the 
child was transferred in the ICU, intubated 
oro-tracheal and mechanically ventilated. 
Postoperative brain CT-scan confirmed the 
gross-total resection, and showed no signs 
of postoperative hemorrhage (Figure 3). 
The spinal MRI showed no signs of 
dissemination. After 3 weeks she was 
transferred in a neuromotor rehabilitation 
centre (GOS= SD).  
The histopatological diagnosis was 
PNET, which was confirmed by the 
immunohistochemical tests. The patient 
was referred to the oncologist. The 
oncologic treatment was chemotherapy and 
radiotherapy of the entire craniospinal axis.  
Follow-up: At the one month follow-up 
visit the child’s neurological state had 
improved and brain MRI showed no signs 
of tumor recurrence (Figure 4). At the 4 
months postoperative visit,GOS was MD – 
the child was conscious, with left 
hemiparesis (ASIA 4), with partial right 
third nerve palsy. Brain MRI (Figure 5) 
showed no signs of tumor recurrence.  
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Figure 3 Postoperative CT-scan 
 
 
Figure 4 One month postoperative MRI 
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Figure 5 Four months postoperative MRI 
 
 
Figure 6 One year postoperative MRI 
 
 
 
 
560          Iulia Vapor et al          Supratentorial neuroectodermal tumor 
 
 
 
The next follow-up visits were made at 
one year postoperative and, also, the brain 
MRI (Figure 6) showed no signs of tumor 
recurrence and the neurologic status had 
improved. In the future for follow-up will 
be made a brain MRI every 6 months, or 
faster if the neurological status impose so. 
Discussions  
The entity of S-PNET was described for 
the first time in 1973 by Hart and Earl. 
Over the time there had been divergences 
in classifying those tumors. For example in 
the WHO classification published in 1993, 
S-PNET and medulloblastomas were 
classified as embryonal tumors with 
multipotent differentiation. Until the 2000 
publication of the WHO classification, 
medulloblastomas were considered 
infratentorial PNET and until then, those 
two types of tumors were studied together. 
In the 2000 published WHO classification 
those entities were separated in two distinct 
subtypes of embryonal tumors. In the most 
recent WHO classification (2007) the 
tumors categorized as S-PNET were CNS 
neuroblastomas, CNS 
Ganglioneuroblastomas, Medulloblastomas 
and Ependymoblastomas. Due to those 
divergences there are relatively few studies 
focalized on S-PNET in the literature.  
S-PNETs are malignant embryonal 
tumors which can be phenotypically poorly 
differentiated or can show different degrees 
of differentiation along neuronal, astrocytic 
and ependymal lines. Tumors with 
neuronal differentiation are termed CNS 
neuroblastomas, if also neuroplastic 
ganglion cells are present, the term is CNS 
ganglioneuroblastoma. Tumors presenting 
features of the embryonal neural tube 
formation are named medulloepitheliomas 
and those with ependymoblastic rosettes are 
termed ependymoblastomas. All those types 
of tumors (which in the previous 
classifications were different entities) are 
variants of CNS PNETs. In this 
classification is described an unusual PNET 
called “embryonal tumor with abundant 
neuropil and true rosettes” and can occur in 
the cerebrum, brain stem and cerebellum of 
young children.  
Despite the progress made in the 
management of S-PNETs the prognostic 
remains poor. The majority of studies 
included patients with tumors categorized 
as PNET before the last WHO 
classification.Biswas and co. found a 5 years 
survival rate of 9% (study of 11 patients 
with S-PNET published in 2009).In the 
CCG 921 trial were included 44 patients 
with S-PNETs and the PFS at 3 years was 
33%, the factors of negative prognosis being 
metastatic disease (all patients with 
metastatic disease died) and young age. In 
German HIT 88/89 and HIT 91 trials were 
enrolled 63 patients with S-PNET and the 
3 years PFS was 39,1%. 
S-PNETs can disseminate via CSF 
(Cerebrospinal fluid) or can generate 
extraneural metastases. Rubens and co. 
reported a case of a small child (23 months 
old) with lung metastases but with long 
survival. Extraneural metastases are very 
rare, more frequent in medulloblastomas 
than in S-PNETs. Craniospinal metastases 
occur in approximately 17-27% of S-
PNETs and the presence of dissemination 
at the moment of diagnosis is a poor 
prognostic factor. This dissemination can 
be detected using CSF cytology (lumbar or 
intracranial) or by using neuroimaging 
techniques (MRI of full neuraxis). There is 
a percent of divergences between those 
methods of detecting craniospinal 
dissemination. However, most treatment 
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protocols recommend the use of CSF 
cytology obtained by lumbar tap. 
The positive cytology without MRI 
findings of metastases can suggest an early 
stage of dissemination. Terterov and co. 
found that MRI findings are correlated with 
survival, whereas perioperative CSF 
cytology does not. Some studies try to 
evaluate with accuracy the best method for 
the diagnosis of craniospinal dissemination 
and the opportunity to avoid the irradiation 
of the entire neuraxis in cases of localized 
disease to avoid the post irradiation 
complications.  
In the case we presented that the child 
had no craniospinal dissemination, but the 
oncologist decided, in accordance with 
current protocols, to do irradiation of the 
entire craniospinal axis after chemotherapy.  
 Another factor that has impact on the 
survival is the grade of resection. Usually 
those tumors are located in eloquent areas 
ant gross total resection cannot be 
accomplished. In the CCG 921 study 
authors found that the dimensions of the 
residual tumor is an important prognostic 
factor, but only in patients with localized 
disease. In the case which we presented the 
postoperative CT-scan confirmed the gross 
total resection and the 1, 4 and 12 months 
postoperative brain MRI showed no signs 
of tumor recurrence. The good 
postoperative course is in accordance with 
the current literature (GTR and no signs of 
disseminated disease), but there may be 
other factors that contribute to that 
evolution. There is necessarily to continue 
the study of this entity in order to identify 
other prognostic factors and new treatment 
strategies to improve the survival period 
and the quality of life of pediatric patients 
with S-PNET. In CCG 921 and in the 
German HIT trials GTR could be 
accomplished in just 40% of the cases of S-
PNETs. In those two studies the amount of 
residual tumor was not a prognostic factor, 
probably due to the small number of cases, 
but there was a tendency for a better 
survival in children with less residual 
tumor.  
Another prognostic factor is the age. 
Small children have a worse prognostic, 
although it is difficult to establish if age 
itself is a prognostic factor due to the fact 
that children younger than 3 years cannot 
undergo radiotherapy. In children younger 
than 3 years old, radiotherapy can cause 
significant late effects such as endocrine 
abnormalities, impaired axial growth, 
hearing impairment, neuropsychological 
dysfunction and secondary tumors. In the 
French Society of Pediatric Oncology 
infant study, the median survival period in 
patients with S-PNET was 12 months and 
the 2 years PFS was 4%. 
The MRI appearance of S-PNETs is 
very heterogeneous. Usually there are big 
lesions, without or with minimal 
surrounding edema, and can show cystic 
degeneration, necrosis, and intratumoral 
hemorrhage.  
In present the majority of studies 
referring to the S-PNETs focus on the 
different strategies of chemotherapy and the 
identification of target molecules for 
adjuvant therapies.  
Also new methods of treatment are 
developed. Pinakin and co published a case 
of treatment of S-PNET located in right 
thalamus extended into the right midbrain, 
using magnetic-resonance-guided laser-
induced thermal therapy, with good results 
at 6 months of follow-up. This method 
may be promising for tumors located in 
high-eloquent areas. 
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Conclusion 
We presented a case of a small child with 
S-PNET admitted in the hospital with 
intratumoral hemorrhage and poor 
neurological status, without signs of 
disseminated disease, but with good 
postoperative evolution after gross total 
resection, chemotherapy and irradiation of 
the entire neuraxis. Although in the last 
years the survival period of those children 
has improved, is necessary to develop new 
strategies to improve the quality of life and 
survival in pediatric patients with S-
PNETs. 
 
Abbreviations 
S-PNET = supratentorial 
neuroectodermal tumor; GCS = Glasgow 
Coma Scale; CT = computed tomography; 
WHO = World Health Organization; CNS 
= Central Nervous System; GOS = 
Glasgow Outcome Scale; MD = Moderate 
Disability; ICU = Intensive Care Unit; 
PFS = Progression Free Survival; CSF = 
Cerebrospinal Fluid; GTR = Gross Total 
Resection; MRI = Magnetic Resonance 
Imaging. 
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